NEWTOWN, PA., March 01, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President and Chief Executive Officer,
Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Thursday, March 11, 2021 NEWTOWN, Pa., March 04, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients
Conference call begins at 4:30 p.m. Eastern time today NEWTOWN, Pa., March 11, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for patients with cancer, announces
NEWTOWN, Pa., March 29, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”) , a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President and Chief
Corporate Partner HanX Biopharmaceuticals enrolled third patient in 80 mg group NEWTOWN, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer,
NEWTOWN, Pa., April 22, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced today that the first patient has been dosed in an investigator-initiated
Company to host conference call and webcast at 4:30 p.m. Eastern Time on Monday, May 17. NEWTOWN, Pa., May 10, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with
Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced
NEWTOWN, Pa., May 20, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX) (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced a one-for-fifteen reverse stock split of
Phase 1 study to evaluate ON 123300 in advanced cancer patients including HR+ HER 2- metastatic breast cancer patients resistant to approved CDK 4/6 inhibitors NEWTOWN, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a clinical-stage biopharmaceutical company
NEWTOWN, Pa., June 01, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Mark Gelder, M.D.
NEWTOWN, Pa., June 03, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Onconova has been selected to present at 2021 BIO
NEWTOWN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that members of the Company’s management team will
Rigosertib synergistically combined with immune checkpoint blockade (ICB) to improve tumor growth inhibition and survival in a murine melanoma model that did not respond to ICB alone Rigosertib’s anti-cancer activity was due to its ability to reverse immunosuppressive tumor microenvironments Data
NEWTOWN, Pa., June 22, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that on June 17, 2021 it received a letter from The Nasdaq Stock Market LLC